[go: up one dir, main page]

US10098921B2 - Method for treating gout and gout-induced arthritis using composition containing mixed extract of Chrysanthemum indicum and Cinnamomum cassia - Google Patents

Method for treating gout and gout-induced arthritis using composition containing mixed extract of Chrysanthemum indicum and Cinnamomum cassia Download PDF

Info

Publication number
US10098921B2
US10098921B2 US15/539,239 US201515539239A US10098921B2 US 10098921 B2 US10098921 B2 US 10098921B2 US 201515539239 A US201515539239 A US 201515539239A US 10098921 B2 US10098921 B2 US 10098921B2
Authority
US
United States
Prior art keywords
extract
cinnamomum cassia
chrysanthemum indicum
gout
mixed extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US15/539,239
Other versions
US20170354703A1 (en
Inventor
Dong Seon Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Institute of Oriental Medicine KIOM
Original Assignee
Korea Institute of Oriental Medicine KIOM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Korea Institute of Oriental Medicine KIOM filed Critical Korea Institute of Oriental Medicine KIOM
Assigned to KOREA INSTITUTE OF ORIENTAL MEDICINE reassignment KOREA INSTITUTE OF ORIENTAL MEDICINE ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KIM, DONG SEON
Publication of US20170354703A1 publication Critical patent/US20170354703A1/en
Application granted granted Critical
Publication of US10098921B2 publication Critical patent/US10098921B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287—Chrysanthemum, e.g. daisy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

  • the present invention relates to an anti-gout composition containing a mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
  • Gout refers to a disease that is caused by deposition of monosodium urate monohydrate crystals (MSU) in articular cartilage, tendons, or surrounding tissues. MSU are generated due to an increase in the uric acid content in blood, wherein the uric acid is the residue of body's metabolism regarding purine which is intaken through food.
  • MSU monosodium urate monohydrate crystals
  • the causes of increased gouty arthritis include westernization of diet, increased obesity, aging of the population, increased prevalence of renal disease and hypertension, increased use of diuretics such as thiazide, and low-dose aspirin, etc.
  • gout is a very common inflammatory arthritis among male adults. It is known that the prevalence rate is about 1% to 2% in western countries, and the incidence of disease is lower in Asians compared to Westerners. However, recently, the prevalence rate has been increased in Western and Asian countries due to westernized eating habits and lifestyle. Even in South Korea, 9.3% of adults (14.3% of men, 2.2% of women) are found to have hyperuricemia. Gout is a type of adult disease that easily occurs in obese men. Uric acid increased in the blood is deposited in the form of MSU in the joints or surrounding tissues, causing inflammation, causing pain, swelling, and, in severe cases, deformation of joints. The disease progresses from the period during which the uric acid level in the blood is increased without symptoms, to the period during which acute intermittent arthritis develops and then chronic gouty arthritis develops with deformation of the joints.
  • Gout is known to have a clear and successful treatment therefor, but it is often accompanied by other diseases such as hypertension and chronic renal failure. Therefore, side effects of medication should be carefully considered, and, as a non-pharmacological treatment, patients' efforts to change their own lifestyles are essential for good prognosis in long-term treatment.
  • Gout and hyperuricemia show clinical manifestations of hypertension, hyperlipidemia, hyperglycemia, and abdominal obesity. Although they are not the diagnostic criteria for the metabolic syndrome, which is a complex disorder that increases the risk of adult diseases such as arteriosclerotic heart disease and type 2 diabetes, gout and hyperuricemia seem to be closely related to the metabolic syndrome. In South Korea, it was reported that 44% of gout patients were accompanied by metabolic syndrome.
  • Gout usually occurs in the form of acute monoarthritis, but, in some cases, may invade small number of joints or, rarely, multiple joints.
  • Non-steroidal anti-inflammatory drugs NSAIDs
  • colchicine and steroids suppress the inflammatory response by inhibiting the activity and migration of leukocytes, and are all drugs that can effectively treat gout attacks; and selectively, cyclooxygenase (COX-2) inhibitors are known to have the same effect as existing non-steroidal anti-inflammatory drugs.
  • COX-2 cyclooxygenase
  • Uric acid-lowering agents are classified into a xanthine oxidase (XO) inhibitor and a uricosuric agent according to a mechanism.
  • XO xanthine oxidase
  • uricosuric agent As uric acid-synthesis inhibitors, there are allopurinol, which is widely used, and febuxostat, which has been recently developed as a new drug.
  • Allopurinol is an XO inhibitor that can be effectively used regardless of the cause of hyperuricemia, but the most serious side effect of allopurinol is hypersensitivity syndrome with fever, rash, an increase in eosinophils, hepatitis, renal failure, and the risk of death.
  • Febuxostat is also known as XO inhibitor, but, unlike allopurinol, it is a nonpurine selective blocking agent that is metabolized mainly in the liver to form glucuronide. Most cases of gout progress into the chronic phase, and, even if there are no symptoms, in a prophylactic way, gout is treated by using anti-inflammatory drugs and a method of lowering the uric acid concentration.
  • prophylactic treatments should be used after the disease has been maintained for a period of time in a calm state, otherwise the gout will recur more severely.
  • prophylactic treatments with existing drugs are not enough to prevent acute episodes of intermittent recurrence of gout, and the technology for inhibiting oxidase, which is a gout-inducing enzyme, with natural products is still insufficient.
  • Cinnamomum cassia has been known to be effective as an herbal medicine for people with weak constitution and poor blood circulation to promote immunity (Korean Patent No. 0842053). Also, disclosed are a Cinnamomum cassia extract-containing composition for prevention and treatment of arteriosclerosis (Korea Patent No. 0294091), a cosmetic composition containing the extract of Cinnamomum cassia (Korean Patent Laid-Open No. 2001-0018668), and a composition for promoting oral hygiene containing a nanoparticulate Cinnamomum cassia extract (Korea Patent No. 0489267).
  • the enhanced effect on gout suppression of the anti-gout composition including the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient has not been disclosed.
  • the present invention has been made in view of the above-mentioned needs, and an object of the present invention is to provide an anti-gout composition which contains a mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient. More particularly, a xanthine oxidase inhibition rate of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia was markedly improved as compared with when the extract of Chrysanthemum indicum or the extract of Cinnamomum cassia is used separately, thereby completing the present invention.
  • the present invention provides an anti-gout composition which contains a mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
  • One or more embodiments of the present invention provide a health functional food for prevention or improvement of gout, containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
  • One or more embodiments of the present invention provide a pharmaceutical composition for prevention or treatment of gout, containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
  • One or more embodiments of the present invention provide a pharmaceutical composition for prevention or treatment of gout-induced arthritis, containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
  • the present invention relates to an anti-gout composition containing a mixed extract of Chrysanthemum indicum and Cinnamomum cassia .
  • the composition inhibits xanthine oxidase, which is a gout-inducing enzyme, and reduces the amount of uric acid in urine, thereby preventing, improving or treating gout.
  • FIG. 1 shows the results obtained by confirming the inhibitory activity of a mixed extract of Chrysanthemum indicum ( C. indicum ) and Cinnamomum cassia ( C. cassia ) according to the present invention on xanthine oxidase.
  • FIG. 2 shows the results obtained by confirming the amount of uric acid contained in the urine according to the treatments of 50, 100, and 200 mg/kg/day of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention.
  • * and *** indicate that there is a statistically significant difference in the amount of uric acid in the urine between a group treated with allopurinol and a group treated with 50, 100, or 200 mg/kg/day of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia , these groups being compared with a hyperuricemia-induced group; and in the case of *, the p value is less than 0.05, and in the case of ***, the p value is less than 0.001.
  • FIG. 3 shows the results obtained by confirming the amount of uric acid contained in the urine according to the treatment of 100 mg/kg/day of the Chrysanthemum indicum extract, 100 mg/kg/day of the Cinnamomum cassia extract, and 100 mg/kg/day of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention.
  • FIG. 4 shows the results obtained by confirming the amount of uric acid contained in serum according to the treatment of 100 mg/kg/day of the Chrysanthemum indicum extract, 100 mg/kg/day of the Cinnamomum cassia extract, and 100 mg/kg/day of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention.
  • One or more embodiments of the present invention provide an anti-gout composition containing a mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
  • the mixed extract of Chrysanthemum indicum and Cinnamomum cassia may be obtained by using water, ethanol, or a mixed solvent thereof, but is not limited thereto.
  • a mixture weight ratio of Chrysanthemum indicum extract and Cinnamomum cassia extract in the mixed extract may be in a range of 1:0.1 to 1:10, for example, 1:1.
  • the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention may be obtained by obtaining Chrysanthemum indicum extract and Cinnamomum cassia extract separately and then mixing those extracts.
  • Chrysanthemum indicum and Cinnamomum cassia may be mixed, and then, the mixture is subjected to an extracting process to obtain the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention.
  • Chrysanthemum indicum used herein refer to every part of the plant including flowers, leaves, stems and roots, and Cinnamomum cassia refers to a medicinal material made of a bark of Japanese Cinnamon.
  • the mixed extract of Chrysanthemum indicum and Cinnamomum cassia inhibits xanthine oxidase.
  • Another aspect of the present invention provides a health functional food for prevention or improvement of gout, containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
  • the health functional food for prevention or improvement of gout containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia may be prepared in any form selected from beverage, pill, tablet, capsule, and powder, or may be prepared by adding the mixed extract to other food or ingredients of food, and may be suitably prepared according to a conventional method.
  • Examples of the foods to which the mixed extract of Chrysanthemum indicum and Cinnamomum cassia is to be added include meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, instant noodles, other noodles, gum, dairy products including ice cream, soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes.
  • the foods used herein refer to any food that is considered as a health-supplementary food in a conventional sense.
  • the health functional foods may include various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, alkynic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like.
  • the health functional foods may also include natural fruit juices and fruit flesh for the production of vegetable drinks. These components may be used independently or in combination.
  • the health functional food according to the present invention may further contain various flavors or natural carbohydrates as an additional ingredient.
  • natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • a sweetening agent natural sweetening agents such as thaumatin and stevia extract, or synthetic sweetening agents such as saccharin and aspartame may be used.
  • Another aspect of the present invention provides a pharmaceutical composition for prevention or treatment of gout containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
  • the pharmaceutical composition according to the present invention may further include a carrier, an excipient, or a diluent in addition to the mixed extract of Chrysanthemum indicum and Cinnamomum cassia .
  • Examples of the carrier, excipient and diluent which may be included in the pharmaceutical composition according to the present invention include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, and magnesium stearate.
  • the examples of the carrier, excipient and diluent are not limited thereto.
  • the pharmaceutical composition may be administered orally or parenterally in a conventional manner.
  • a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or the like, may be used in the formulation process.
  • Solid formulations for oral administration include tablets, pills, powder, granules, capsules and the like, and these solid formulations are prepared by mixing with at least one excipient selected from starch, calcium carbonate, sucrose, lactose, gelatin, and the like.
  • lubricants such as magnesium stearate and talc may also be used.
  • Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups and the like.
  • excipients such as wetting agents, sweeteners, fragrances, preservatives and the like, may be included in addition to water and liquid paraffin, which are simple diluents commonly used.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like.
  • suppository bases include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin, and the like.
  • Another aspect of the present invention provides a pharmaceutical composition for prevention or treatment of gout-induced arthritis containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
  • Cinnamomum cassia water extract were mixed at a weight ratio of 1:1 to prepare a mixed water extract of Chrysanthemum indicum and Cinnamomum cassia.
  • the mixed extract prepared according to Example 1 was diluted 5-fold and then 0.2 ml of a substrate solution, obtained by dissolving 2 mM of xanthine in 0.1 ml of the diluted solution and 0.6 ml of 0.1 M potassium phosphate buffer (pH 7.5), was added thereto.
  • 0.1 ml of xanthine oxidase (0.2 U/ml) was added thereto and the reaction was carried out at 37 ⁇ for 5 minutes.
  • 1 ml of 1N HCl was added to stop the reaction, and the absorbance of uric acid produced in the reaction solution was measured at a wavelength of 292 nm.
  • the inhibitory activity of the mixed extract on xanthine oxidase was shown by the percentage (%) of the absorbance reduction in a group treated with or without a sample.
  • the Chrysanthemum indicum ethanol extract and the Cinnamomum cassia ethanol extract were each diluted in the same manner as applied to the mixed extract, and their inhibitory activities on xanthine oxidase were measured in the same manner as used for the mixed extract. Results obtained therefrom are shown in FIG. 1 .
  • Potassium oxonate (150 mg/kg, 0.5% sodium carboxymethylcellulose (CMC-Na with 0.1 M sodium acetate, pH 5)) was intraperitoneally injected to SD-rats, which is a gout animal model, to induce hyperuricemia. After 24 hours, urine was collected from the rats, and hyperacidemia-induced rats were selected therefrom using a QuantiChromTM Uric Acid Assay Kit (DIUA-250, BioAssay Systems, USA). 200 mg/kg, 100 mg/kg, and 50 mg/kg of mixed extracts of Chrysanthemum indicum and Cinnamomum cassia (1:1) were administered to the selected experimental animals.
  • CMC-Na with 0.1 M sodium acetate, pH 5 sodium carboxymethylcellulose
  • the amount of uric acid in the urine was increased to about 50 mg/dL by the administration of potassium oxonate, and due to the administration of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention, the amount of uric acid was decreased to about 32 mg/dL, showing effects similar to those obtained by using allopurinol, which is a positive control.
  • Potassium oxonate 150 mg/kg, 0.5% sodium carboxymethylcellulose (CMC-Na with 0.1 M sodium acetate, pH 5) was intraperitoneally injected to SD-rats, which is a gout animal model, of gout to induce hyperuricemia. After 24 hours, urine was collected from the rats, and hyperacidemia-induced rats were selected therefrom using a QuantiChromTM Uric Acid Assay Kit (DIUA-250, BioAssay Systems, USA).
  • CMC-Na with 0.1 M sodium acetate, pH 5 sodium carboxymethylcellulose
  • the amount of uric acid in the urine was increased to about 53 mg/dL by the administration of potassium oxonate, and due to the administration of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention, the amount of uric acid was decreased to about 31 mg/dL, showing effects similar to those obtained by using allopurinol, which is a positive control.
  • the Chrysanthemum indicum extract and the Cinnamomum cassia extract lead to a decrease to 42 mg/dL and 44 mg/dL, respectively.
  • the amount of uric acid in the blood was increased to about 10.4 mg/dL by the administration of potassium oxonate, and due to the administration of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention, the amount of uric acid was decreased to about 6.3 mg/dL, showing effects similar to those obtained by using allopurinol, which is a positive control.
  • the Chrysanthemum indicum extract and the Cinnamomum cassia extract lead to decreases of 8.9 mg/dL and 8.3 mg/dL, respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

An anti-gout composition including the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient shows substantially greater inhibitory effects on xanthine oxidase than when Chrysanthemum indicum or Cinnamomum cassia is used separately. An animal model treated with the mixed extract of Chrysanthemum indicum and Cinnamomum cassia experienced a decrease in uric acid in serum and in urine. The mixed extract of Chrysanthemum indicum and Cinnamomum cassia is an active ingredient induced from a natural material, and, accordingly, the mixed extract is safe and a source material therefor is easily provided. Accordingly, the mixed extract can be widely used in gout-related industries.

Description

CROSS REFERENCE TO RELATED APPLICATIONS AND CLAIM OF PRIORITY
This application claims benefit under 35 U.S.C. 119(e), 120, 121, or 365(c), and is a National Stage entry from International Application No. PCT/KR2015/013948, filed Dec. 18, 2015, which claims priority to the benefit of Korean Patent Application No. 10-2014-0187418filed in the Korean Intellectual Property Office on Dec. 23, 2014, the entire contents of which are incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to an anti-gout composition containing a mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
BACKGROUND ART
Gout refers to a disease that is caused by deposition of monosodium urate monohydrate crystals (MSU) in articular cartilage, tendons, or surrounding tissues. MSU are generated due to an increase in the uric acid content in blood, wherein the uric acid is the residue of body's metabolism regarding purine which is intaken through food. The causes of increased gouty arthritis include westernization of diet, increased obesity, aging of the population, increased prevalence of renal disease and hypertension, increased use of diuretics such as thiazide, and low-dose aspirin, etc.
In addition, gout is a very common inflammatory arthritis among male adults. It is known that the prevalence rate is about 1% to 2% in western countries, and the incidence of disease is lower in Asians compared to Westerners. However, recently, the prevalence rate has been increased in Western and Asian countries due to westernized eating habits and lifestyle. Even in South Korea, 9.3% of adults (14.3% of men, 2.2% of women) are found to have hyperuricemia. Gout is a type of adult disease that easily occurs in obese men. Uric acid increased in the blood is deposited in the form of MSU in the joints or surrounding tissues, causing inflammation, causing pain, swelling, and, in severe cases, deformation of joints. The disease progresses from the period during which the uric acid level in the blood is increased without symptoms, to the period during which acute intermittent arthritis develops and then chronic gouty arthritis develops with deformation of the joints.
Gout is known to have a clear and successful treatment therefor, but it is often accompanied by other diseases such as hypertension and chronic renal failure. Therefore, side effects of medication should be carefully considered, and, as a non-pharmacological treatment, patients' efforts to change their own lifestyles are essential for good prognosis in long-term treatment. Gout and hyperuricemia show clinical manifestations of hypertension, hyperlipidemia, hyperglycemia, and abdominal obesity. Although they are not the diagnostic criteria for the metabolic syndrome, which is a complex disorder that increases the risk of adult diseases such as arteriosclerotic heart disease and type 2 diabetes, gout and hyperuricemia seem to be closely related to the metabolic syndrome. In South Korea, it was reported that 44% of gout patients were accompanied by metabolic syndrome. Gout usually occurs in the form of acute monoarthritis, but, in some cases, may invade small number of joints or, rarely, multiple joints. Non-steroidal anti-inflammatory drugs (NSAIDs), which are used in the treatment of acute gout, are well known for inhibiting the inflammatory response; colchicine and steroids suppress the inflammatory response by inhibiting the activity and migration of leukocytes, and are all drugs that can effectively treat gout attacks; and selectively, cyclooxygenase (COX-2) inhibitors are known to have the same effect as existing non-steroidal anti-inflammatory drugs.
In addition, when the uric acid concentration in blood is maintained to a level below the saturation level for a long period of time, the size of existing gout tophi is reduced while acute gouty arthritis is prevented. In the chronic phase of gout, the treatment therefor is carried out to lower the concentration of uric acid in the blood. Uric acid-lowering agents are classified into a xanthine oxidase (XO) inhibitor and a uricosuric agent according to a mechanism. As uric acid-synthesis inhibitors, there are allopurinol, which is widely used, and febuxostat, which has been recently developed as a new drug. Allopurinol is an XO inhibitor that can be effectively used regardless of the cause of hyperuricemia, but the most serious side effect of allopurinol is hypersensitivity syndrome with fever, rash, an increase in eosinophils, hepatitis, renal failure, and the risk of death. Febuxostat is also known as XO inhibitor, but, unlike allopurinol, it is a nonpurine selective blocking agent that is metabolized mainly in the liver to form glucuronide. Most cases of gout progress into the chronic phase, and, even if there are no symptoms, in a prophylactic way, gout is treated by using anti-inflammatory drugs and a method of lowering the uric acid concentration. These prophylactic treatments should be used after the disease has been maintained for a period of time in a calm state, otherwise the gout will recur more severely. However, there is a lot of controversy about the clam period of the illness, and even such prophylactic treatments with existing drugs are not enough to prevent acute episodes of intermittent recurrence of gout, and the technology for inhibiting oxidase, which is a gout-inducing enzyme, with natural products is still insufficient.
Gout medicines need to be used chronically. Accordingly, side effects caused by cholchine or allopurinol cause serious problems. Therefore, it is necessary to research into and develop natural products that can prevent inflammation for a prolonged period without any side effects. However, the research and the development have not yet been actively performed. As an example of natural products known to date as research results, the extract of Chrysanthemum indicum disclosed in Patent No. 2014-0106772 is known to have a gout inhibitory effect.
Meanwhile, Cinnamomum cassia has been known to be effective as an herbal medicine for people with weak constitution and poor blood circulation to promote immunity (Korean Patent No. 0842053). Also, disclosed are a Cinnamomum cassia extract-containing composition for prevention and treatment of arteriosclerosis (Korea Patent No. 0294091), a cosmetic composition containing the extract of Cinnamomum cassia (Korean Patent Laid-Open No. 2001-0018668), and a composition for promoting oral hygiene containing a nanoparticulate Cinnamomum cassia extract (Korea Patent No. 0489267).
However, as shown according to the present invention, the enhanced effect on gout suppression of the anti-gout composition including the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient has not been disclosed.
SUMMURY
The present invention has been made in view of the above-mentioned needs, and an object of the present invention is to provide an anti-gout composition which contains a mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient. More particularly, a xanthine oxidase inhibition rate of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia was markedly improved as compared with when the extract of Chrysanthemum indicum or the extract of Cinnamomum cassia is used separately, thereby completing the present invention.
In order to achieve the above objects, the present invention provides an anti-gout composition which contains a mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
One or more embodiments of the present invention provide a health functional food for prevention or improvement of gout, containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
One or more embodiments of the present invention provide a pharmaceutical composition for prevention or treatment of gout, containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
One or more embodiments of the present invention provide a pharmaceutical composition for prevention or treatment of gout-induced arthritis, containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
The present invention relates to an anti-gout composition containing a mixed extract of Chrysanthemum indicum and Cinnamomum cassia. The composition inhibits xanthine oxidase, which is a gout-inducing enzyme, and reduces the amount of uric acid in urine, thereby preventing, improving or treating gout.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows the results obtained by confirming the inhibitory activity of a mixed extract of Chrysanthemum indicum (C. indicum) and Cinnamomum cassia (C. cassia) according to the present invention on xanthine oxidase.
FIG. 2 shows the results obtained by confirming the amount of uric acid contained in the urine according to the treatments of 50, 100, and 200 mg/kg/day of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention. * and *** indicate that there is a statistically significant difference in the amount of uric acid in the urine between a group treated with allopurinol and a group treated with 50, 100, or 200 mg/kg/day of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia, these groups being compared with a hyperuricemia-induced group; and in the case of *, the p value is less than 0.05, and in the case of ***, the p value is less than 0.001.
FIG. 3 shows the results obtained by confirming the amount of uric acid contained in the urine according to the treatment of 100 mg/kg/day of the Chrysanthemum indicum extract, 100 mg/kg/day of the Cinnamomum cassia extract, and 100 mg/kg/day of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention. * and *** indicate that there is a statistically significant difference in the amount of uric acid in the urine among the allopurinol treatment group, a Chrysanthemum indicum extract treatment group, a Cinnamomum cassia extract treatment group, and a group treated with various concentrations of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia, these groups being compared with a hyperuricemia-induced group; and in the case of *, the p value is less than 0.05, and in the case of ***, the p value is less than 0.001.
FIG. 4 shows the results obtained by confirming the amount of uric acid contained in serum according to the treatment of 100 mg/kg/day of the Chrysanthemum indicum extract, 100 mg/kg/day of the Cinnamomum cassia extract, and 100 mg/kg/day of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention. * and *** indicate that there is a statistically significant difference in the amount of uric acid in serum among the allopurinol treatment group, a Chrysanthemum indicum extract treatment group, a Cinnamomum cassia extract treatment group, and a group treated with various concentrations of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia, these groups being compared with a hyperuricemia-induced group; and in the case of *, the p value is less than 0.05, and in the case of ***, the p value is less than 0.001.
 DETAILED DESCRIPTION
One or more embodiments of the present invention provide an anti-gout composition containing a mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
The mixed extract of Chrysanthemum indicum and Cinnamomum cassia may be obtained by using water, ethanol, or a mixed solvent thereof, but is not limited thereto. In one embodiment, a mixture weight ratio of Chrysanthemum indicum extract and Cinnamomum cassia extract in the mixed extract may be in a range of 1:0.1 to 1:10, for example, 1:1.
The mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention may be obtained by obtaining Chrysanthemum indicum extract and Cinnamomum cassia extract separately and then mixing those extracts. However, in other embodiments, Chrysanthemum indicum and Cinnamomum cassia may be mixed, and then, the mixture is subjected to an extracting process to obtain the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention.
Chrysanthemum indicum used herein refer to every part of the plant including flowers, leaves, stems and roots, and Cinnamomum cassia refers to a medicinal material made of a bark of Japanese Cinnamon.
The mixed extract of Chrysanthemum indicum and Cinnamomum cassia inhibits xanthine oxidase.
Another aspect of the present invention provides a health functional food for prevention or improvement of gout, containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
The health functional food for prevention or improvement of gout containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia may be prepared in any form selected from beverage, pill, tablet, capsule, and powder, or may be prepared by adding the mixed extract to other food or ingredients of food, and may be suitably prepared according to a conventional method.
Examples of the foods to which the mixed extract of Chrysanthemum indicum and Cinnamomum cassia is to be added, include meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, instant noodles, other noodles, gum, dairy products including ice cream, soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes. The foods used herein refer to any food that is considered as a health-supplementary food in a conventional sense.
The health functional foods may include various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate etc.), pectic acid and its salts, alkynic acid and its salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks, and the like. The health functional foods may also include natural fruit juices and fruit flesh for the production of vegetable drinks. These components may be used independently or in combination.
The health functional food according to the present invention may further contain various flavors or natural carbohydrates as an additional ingredient. Examples of the natural carbohydrates include monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a sweetening agent, natural sweetening agents such as thaumatin and stevia extract, or synthetic sweetening agents such as saccharin and aspartame may be used.
Another aspect of the present invention provides a pharmaceutical composition for prevention or treatment of gout containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient. The pharmaceutical composition according to the present invention may further include a carrier, an excipient, or a diluent in addition to the mixed extract of Chrysanthemum indicum and Cinnamomum cassia. Examples of the carrier, excipient and diluent which may be included in the pharmaceutical composition according to the present invention, include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate , cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, and magnesium stearate. However, the examples of the carrier, excipient and diluent are not limited thereto.
In addition, the pharmaceutical composition may be administered orally or parenterally in a conventional manner. When the pharmaceutical composition is formulated, a diluent or excipient, such as a filler, an extender, a binder, a wetting agent, a disintegrant, a surfactant, or the like, may be used in the formulation process. Solid formulations for oral administration include tablets, pills, powder, granules, capsules and the like, and these solid formulations are prepared by mixing with at least one excipient selected from starch, calcium carbonate, sucrose, lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. Liquid formulations for oral administration include suspensions, solutions, emulsions, syrups and the like. Various excipients, such as wetting agents, sweeteners, fragrances, preservatives and the like, may be included in addition to water and liquid paraffin, which are simple diluents commonly used. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories. Examples of the non-aqueous solvent and the suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. Examples of suppository bases include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin, and the like.
Another aspect of the present invention provides a pharmaceutical composition for prevention or treatment of gout-induced arthritis containing the mixed extract of Chrysanthemum indicum and Cinnamomum cassia as an active ingredient.
Hereinafter, the present invention will be described in more detail with reference to Examples. Those skilled in the art may understand that these examples are only for describing the present invention in detail and that the scope of the present invention is not limited thereto.
EXAMPLE 1 Preparation of Mixed Ethanol Extract of Chrysanthemum indicum and Cinnamomum cassia
15 l of 70% ethanol was added to 1 kg of Chrysanthemum indicum and 1 kg of Cinnamomum cassia, separately, and each of the mixtures was subjected to an extraction process at a temperature of 85□ for 3 hours. Filtrates obtained therefrom were concentrated under reduced pressure at 50□, thereby obtaining 95 g of Chrysanthemum indicum ethanol extract and 77 g of Cinnamomum cassia ethanol extract. The Chrysanthemum indicum ethanol extract and the Cinnamomum cassia ethanol extract were mixed at a weight ratio of 1:1 to prepare a mixed ethanol extract of Chrysanthemum indicum and Cinnamomum cassia.
EXAMPLE 2 Preparation of Mixed Water Extract of Chrysanthemum indicum and Cinnamomum cassia
15 l of purified water was added to 1 kg of Chrysanthemum indicum and 1 kg of Cinnamomum cassia, separately, and each of the mixtures was subjected to an extraction process at a temperature of 100□ for 3 hours. Filtrates obtained therefrom were concentrated under reduced pressure at 55□, thereby obtaining 146 g of Chrysanthemum indicum ethanol extract and 110 g of Cinnamomum cassia ethanol extract. The Chrysanthemum indicum water extract and the
Cinnamomum cassia water extract were mixed at a weight ratio of 1:1 to prepare a mixed water extract of Chrysanthemum indicum and Cinnamomum cassia.
EXAMPLE 3 Inhibitory Activity of Mixed Ethanol Extract of Chrysanthemum indicum and Cinnamomum cassia on Xanthine Oxidase
Inhibitory activity of the mixed ethanol extract of Chrysanthemum indicum and Cinnamomum cassia prepared according to Example 1 on xanthine oxidase was analyzed. The inhibitory activity of xanthine oxidase was analyzed by using the method presented by Sirpe and Della Corte [Stirpe F, Della Corte E. 1969. The regulation of rat liver xanthine oxidase. J Biol Chem 244: 3855-3563].
The mixed extract prepared according to Example 1 was diluted 5-fold and then 0.2 ml of a substrate solution, obtained by dissolving 2 mM of xanthine in 0.1 ml of the diluted solution and 0.6 ml of 0.1 M potassium phosphate buffer (pH 7.5), was added thereto. 0.1 ml of xanthine oxidase (0.2 U/ml) was added thereto and the reaction was carried out at 37□ for 5 minutes. Then, 1 ml of 1N HCl was added to stop the reaction, and the absorbance of uric acid produced in the reaction solution was measured at a wavelength of 292 nm. The inhibitory activity of the mixed extract on xanthine oxidase was shown by the percentage (%) of the absorbance reduction in a group treated with or without a sample. As a control, instead of the mixed extract, the Chrysanthemum indicum ethanol extract and the Cinnamomum cassia ethanol extract were each diluted in the same manner as applied to the mixed extract, and their inhibitory activities on xanthine oxidase were measured in the same manner as used for the mixed extract. Results obtained therefrom are shown in FIG. 1.
As a result, it was confirmed that, compared with when the same concentration of the Chrysanthemum indicum extract or Cinnamomum cassia extract was used separately, the mixed extract of Chrysanthemum indicum and Cinnamomum cassia showed a statistically significant synergistic inhibitory activity on xanthine oxidase.
EXAMPLE 4 Uric Acid-Reducing Effects in Urine of Gout-Induced Animal Model
Potassium oxonate (150 mg/kg, 0.5% sodium carboxymethylcellulose (CMC-Na with 0.1 M sodium acetate, pH 5)) was intraperitoneally injected to SD-rats, which is a gout animal model, to induce hyperuricemia. After 24 hours, urine was collected from the rats, and hyperacidemia-induced rats were selected therefrom using a QuantiChrom™ Uric Acid Assay Kit (DIUA-250, BioAssay Systems, USA). 200 mg/kg, 100 mg/kg, and 50 mg/kg of mixed extracts of Chrysanthemum indicum and Cinnamomum cassia (1:1) were administered to the selected experimental animals. Similarly, as a positive control, 50 mg/kg allopurinol was suspended in a 0.01 M PBS buffer containing 0.1% polyoxyethylene sorbitan monolate, and the result was orally administered for 3 days and, on the day just before the autopsy, the rats were fasted for 16 hours.
After the last oral administration, urine was collected for 2 hours, and the rats were anesthetized with ethyl ether and the blood was taken therefrom. The amount of urine acid in the blood was measured using a QuantiChrom ™ Uric Acid Assay kit (DIUA-250, BioAssay Systems, USA).
As shown in FIG. 2, the amount of uric acid in the urine was increased to about 50 mg/dL by the administration of potassium oxonate, and due to the administration of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention, the amount of uric acid was decreased to about 32 mg/dL, showing effects similar to those obtained by using allopurinol, which is a positive control.
EXAMPLE 5 Synergistic Effect of Chrysanthemum indicum Extract and Cinnamomum cassia Extract on Reduction of Uric Acid in Blood and Urine of Gout-Induced Animal Model
Potassium oxonate (150 mg/kg, 0.5% sodium carboxymethylcellulose (CMC-Na with 0.1 M sodium acetate, pH 5)) was intraperitoneally injected to SD-rats, which is a gout animal model, of gout to induce hyperuricemia. After 24 hours, urine was collected from the rats, and hyperacidemia-induced rats were selected therefrom using a QuantiChrom™ Uric Acid Assay Kit (DIUA-250, BioAssay Systems, USA). 100 mg/kg of the Chrysanthemum indicum extract, 100 mg/kg of the Cinnamomum cassia extract, and 100 mg/kg of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia (1:1) were administered to the selected experimental animals. Similarly, as a positive control, 50 mg/kg allopurinol was suspended in a 0.01 M PBS buffer containing 0.1% polyoxyethylene sorbitan monolate, and the result was orally administered for 3 days and, on the day just before the autopsy, the rats were fasted for 16 hours After the last oral administration, urine was collected for 2 hours, and the rats were anesthetized with ethyl ether and the blood was taken therefrom. The amount of urine acid in the blood was measured using a QuantiChrom ™ Uric Acid Assay kit (DIUA-250, BioAssay Systems, USA).
As shown in FIG. 3, the amount of uric acid in the urine was increased to about 53 mg/dL by the administration of potassium oxonate, and due to the administration of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention, the amount of uric acid was decreased to about 31 mg/dL, showing effects similar to those obtained by using allopurinol, which is a positive control. On the other hand, the Chrysanthemum indicum extract and the Cinnamomum cassia extract lead to a decrease to 42 mg/dL and 44 mg/dL, respectively. That is, the reduction effect of each of these extracts was smaller than that of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia. Accordingly, it was confirmed that the mixing of the Chrysanthemum indicum extract and the Cinnamomum cassia extract contributed to the synergistic effect.
As shown in FIG. 4, the amount of uric acid in the blood was increased to about 10.4 mg/dL by the administration of potassium oxonate, and due to the administration of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia according to the present invention, the amount of uric acid was decreased to about 6.3 mg/dL, showing effects similar to those obtained by using allopurinol, which is a positive control. On the other hand, the Chrysanthemum indicum extract and the Cinnamomum cassia extract lead to decreases of 8.9 mg/dL and 8.3 mg/dL, respectively. That is, the reduction effect of each of these extracts were smaller than those of the mixed extract of Chrysanthemum indicum and Cinnamomum cassia. Accordingly, it was confirmed that the mixing of the Chrysanthemum indicum extract and the Cinnamomum cassia extract contributed to the synergistic effect.

Claims (6)

The invention claimed is:
1. A method for treating gout in a subject, the method comprising:
administering to the subject having gout a therapeutic amount of a composition comprising a mixed extract of Chrysanthemum indicum extract and Cinnamomum cassia extract at a weight ratio of 1:0.1 to 1:10 as an active ingredient.
2. The method of claim 1, wherein the composition further comprises an additive selected from the group consisting of a carrier, an excipient, and a diluent.
3. The method of claim 1, wherein the mixed extract is prepared by using a solvent selected from the group consisting of water and/or ethanol to obtain the Chrysanthemum indicum extract and the Cinnamomum cassia extract and mixing the Chrysanthemum indicum extract and the Cinnamomum cassia extract.
4. A method for treating gout-induced arthritis in a subject, the method comprising:
administering to the subject having gout-induced arthritis a therapeutic amount of a composition comprising a mixed extract of Chrysanthemum indicum extract and Cinnamomum cassia extract at a weight ratio of 1:0.1 to 1:10 as an active ingredient.
5. The method of claim 4, wherein the composition further comprises an additive selected from the group consisting of a carrier, an excipient, and a diluent.
6. The method of claim 4, wherein the mixed extract is prepared by using a solvent selected from the group consisting of water and/or ethanol to obtain the Chrysanthemum indicum extract and the Cinnamomum cassia extract and mixing the Chrysanthemum indicum extract and the Cinnamomum cassia extract.
US15/539,239 2014-12-23 2015-12-18 Method for treating gout and gout-induced arthritis using composition containing mixed extract of Chrysanthemum indicum and Cinnamomum cassia Active US10098921B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2014-0187418 2014-12-23
KR1020140187418A KR101642124B1 (en) 2014-12-23 2014-12-23 Composition for inhibition of gout comprising mixed extract of Chrysanthemum indicum and Cinnamomum cassia as effective component
PCT/KR2015/013948 WO2016105035A2 (en) 2014-12-23 2015-12-18 Anti-gout composition containing mixture extract of chrysanthemum indicum and cinnamomum cassia as active ingredient

Publications (2)

Publication Number Publication Date
US20170354703A1 US20170354703A1 (en) 2017-12-14
US10098921B2 true US10098921B2 (en) 2018-10-16

Family

ID=56151583

Family Applications (1)

Application Number Title Priority Date Filing Date
US15/539,239 Active US10098921B2 (en) 2014-12-23 2015-12-18 Method for treating gout and gout-induced arthritis using composition containing mixed extract of Chrysanthemum indicum and Cinnamomum cassia

Country Status (6)

Country Link
US (1) US10098921B2 (en)
EP (1) EP3238732A4 (en)
JP (1) JP6423537B2 (en)
KR (1) KR101642124B1 (en)
CN (1) CN107106623A (en)
WO (1) WO2016105035A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102187877B1 (en) * 2020-03-25 2020-12-07 주식회사 프롬바이오 Composition for ameliorating, preventing or treating hyperuricemia or gout comprising extract of Chrysanthemum indicum L. and Cornus officinalis
CN112426461B (en) * 2020-12-22 2022-02-08 江西中医药大学 Traditional Chinese medicine composition for treating gouty arthritis and preparation method and application thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010018668A (en) 1999-08-20 2001-03-15 유상옥 A cosmetic composition containing Cinnamomi Cortex extracts
KR100294091B1 (en) 1998-06-10 2001-07-12 정명식 Composition for preventing and treating atherosclerosis comprising extract of cinnamon bark or alpiniae katsumadaii semen
JP2002121145A (en) 2000-10-16 2002-04-23 Fancl Corp Xanthine oxidase inhibitor
KR100429244B1 (en) 2001-04-30 2004-04-28 매일유업주식회사 Herb drink including of deer antler and material of herbal medicine
KR20040080640A (en) 2003-03-12 2004-09-20 주식회사 한국토종약초연구소 Pharmaceutical composition comprising a fruit extract of Actinidia polygama AP having anti-gout activity
KR100489267B1 (en) 2002-11-27 2005-05-17 유효경 Oral care composition comprising nanoparticulated cinnamon extract
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
KR100842053B1 (en) 2005-10-26 2008-06-30 한국 한의학 연구원 The composition comprising extract of Cinnamomum cassia bark for improving normal flora and enhancing immune response
CN101732386A (en) 2008-11-04 2010-06-16 江苏康缘药业股份有限公司 Medicinal composition for treating gout, preparation method thereof and purposes thereof
CN101829264A (en) 2009-03-11 2010-09-15 江苏中康药物科技有限公司 Medicine composition for treating hyperuricemia and related diseases and preparation method and application thereof
US20110293754A1 (en) 2010-05-28 2011-12-01 Dong-A University Research Foundation For Industry-Academy Cooperation Anticancer composition containing herbal extract
KR20140106772A (en) 2013-02-25 2014-09-04 경북대학교 산학협력단 Composition for inhibition of gout comprising extracts of chrysanthemum indicum L.
US20160220622A1 (en) * 2008-05-02 2016-08-04 Amorepacific Corporation Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same
US20160324776A1 (en) * 2014-05-12 2016-11-10 HDDC Holdings, LLC Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101953984B (en) * 2009-07-17 2015-01-14 江苏康缘药业股份有限公司 Medicinal composition for treating urarthritis, preparation method thereof, preparation thereof and use thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100294091B1 (en) 1998-06-10 2001-07-12 정명식 Composition for preventing and treating atherosclerosis comprising extract of cinnamon bark or alpiniae katsumadaii semen
KR20010018668A (en) 1999-08-20 2001-03-15 유상옥 A cosmetic composition containing Cinnamomi Cortex extracts
JP2002121145A (en) 2000-10-16 2002-04-23 Fancl Corp Xanthine oxidase inhibitor
KR100429244B1 (en) 2001-04-30 2004-04-28 매일유업주식회사 Herb drink including of deer antler and material of herbal medicine
KR100489267B1 (en) 2002-11-27 2005-05-17 유효경 Oral care composition comprising nanoparticulated cinnamon extract
KR20040080640A (en) 2003-03-12 2004-09-20 주식회사 한국토종약초연구소 Pharmaceutical composition comprising a fruit extract of Actinidia polygama AP having anti-gout activity
KR100842053B1 (en) 2005-10-26 2008-06-30 한국 한의학 연구원 The composition comprising extract of Cinnamomum cassia bark for improving normal flora and enhancing immune response
US20080038367A1 (en) * 2006-08-11 2008-02-14 Sal Saloum Nutritional supplement compositions and methods of preparing
US20160220622A1 (en) * 2008-05-02 2016-08-04 Amorepacific Corporation Medicinal plants extract using processing of herbal medicine and composition of skin external application comprising the same
CN101732386A (en) 2008-11-04 2010-06-16 江苏康缘药业股份有限公司 Medicinal composition for treating gout, preparation method thereof and purposes thereof
CN101829264A (en) 2009-03-11 2010-09-15 江苏中康药物科技有限公司 Medicine composition for treating hyperuricemia and related diseases and preparation method and application thereof
US20110293754A1 (en) 2010-05-28 2011-12-01 Dong-A University Research Foundation For Industry-Academy Cooperation Anticancer composition containing herbal extract
KR20140106772A (en) 2013-02-25 2014-09-04 경북대학교 산학협력단 Composition for inhibition of gout comprising extracts of chrysanthemum indicum L.
US20160324776A1 (en) * 2014-05-12 2016-11-10 HDDC Holdings, LLC Cannabinoid caffeinated drinks, powder, beans, and cannabinoid loose tea leaf

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
European Search Report for EP 15873562 from European patent office in a counterpart European patent application dated Jun. 20, 2018.
F. Stirpe et al., "The Regulation of Rat Liver Xanthine Oxidase; Conversion in Vitro of the Enzyme Activity From Dehydrogenase (Type D) to Oxidase (Type 0)", The Journal of Biological Chemistry, vol. 244 (14), pp. 3855-3863, 1969.
International Search Report for PCT/KR2015/013948.
Kong, L. et al. Inhibition of Xanthine Oxidase by Some Chinese Medicinal Plants Used to Treat Gout. J of Ethnopharmacology 73: 199-207, 2000. (Year: 2000). *
L.D. Kong et al., "Inhibition of xanthine oxidase by some Chinese medicinal plants used to treat gout", Journal of Ethnopharmacology, vol. 73, pp. 199-207, 2000.
Lee, Y. et al. Synergistic Uric Acid Lowering Effects of the Combination of Chrysanthemum indicum Linne Flower . . . Evidence Based Complementary and Alternative Medicine 2017:1-9, 2017. (Year: 2017). *
Nguyen M. et al. Xanthine Oxidase Inhibitory Activity of Vietnamese Medicinal Plants. Biological and Pharmaceutical Bulletin 27(9) 1414-1421, Sep. 2004. (Year: 2004). *
Nile S. et al. Screening of Ferulic Acid Related Compounds as Inhibitors of Xanthine Oxidase . . . Brazilian J of Pharmacognosy 26:50-55, 2016. (Year: 2016). *
Office action dated Mar. 6, 2018 from Japan Intellectual Property Office in a counterpart Japanese Patent Application No. 2017-533009 (all the cited references are listed in this IDS.) (English translation is also submitted herewith.).
S.Y. Wang et al., "Essential oil from leaves of Cinnamomum osmophloeum acts as a xanthine oxidase inhibitor and reduces the serum uric acid levels in oxonate-induced mice", Phytomedicine, vol. 15, pp. 940-945, 2008.
Song, H. et al. Screening for Selective Inhibitors of Xanthine Oxidase From Flos Chrysanthemum . . . J of Chromatography B 961:56-61, May 14, 2014. (Year: 2014). *
Wang S. et al. Essential Oil From Leaves of Cinnamomum osmophloeum . . . Phytomedicine 15(11)940-945, Nov. 2008. (Year: 2008). *
Zhao, X. et al. Effects of Cassia Oil on Serum and Hepatic Uric Acid Levels . . . J of Ethnopharmacology 103:357-365, 2006. (Year: 2006). *

Also Published As

Publication number Publication date
EP3238732A2 (en) 2017-11-01
US20170354703A1 (en) 2017-12-14
WO2016105035A2 (en) 2016-06-30
WO2016105035A3 (en) 2016-09-09
KR101642124B1 (en) 2016-07-22
JP2018501245A (en) 2018-01-18
CN107106623A (en) 2017-08-29
JP6423537B2 (en) 2018-11-14
KR20160076853A (en) 2016-07-01
EP3238732A4 (en) 2018-07-18

Similar Documents

Publication Publication Date Title
KR101863604B1 (en) Composition for preventing, improving or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising extract of Alpiniae fructus as effective component
EP2685997B1 (en) Composition comprising the extract of herbal combination for preventing or treating diabetic peripheral neuropathy
US20230082624A1 (en) Composition, containing quisqualis indica extract, for preventing or treating prostatic hyperplasia
KR101737046B1 (en) Pharmaceutical Composition for Preventing or Treating Diabetes Comprising Linalyl Acetate
KR101791034B1 (en) Composition for preventing, improving or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising extract of Allii Radix as effective component
US10098921B2 (en) Method for treating gout and gout-induced arthritis using composition containing mixed extract of Chrysanthemum indicum and Cinnamomum cassia
KR102210646B1 (en) Health functional food composition for promoting uric acid excretion containing cornus milk extract as an active ingredient
KR101881144B1 (en) Composition for preventing, improving or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising Dryopteris crassirhizpma extract as effective component
KR20190113272A (en) Composition for treating, alleviating or preventing non-alcoholic fatty liver disease comprising rosa rugosa thunb extract
KR101168595B1 (en) A composition comprising an extract of Portulaca oleracea for preventing or treating diabetes, diabetic complications
KR102510861B1 (en) Composition for promoting uric acid excretion comprising mixed herb extract as effective component
KR102361526B1 (en) Composition for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising egg shell membrane as effective component
KR20190085767A (en) Composition for preventing, ameliorating or treating hyperuricemia or metabolic disorders associated with hyperuricemia comprising extract or fraction of Hydnocarpi semen or compound derived from Hydnocarpi semen extract as effective component
KR102722880B1 (en) Functional food composition for inhibiting and excreting uric acid containing phytochemicals as active ingredients
KR102460500B1 (en) Composition for inhibiting gout comprising mixture of Scutellaria baicalensis extract and nelumbinis folium extract as active ingredient
KR100842054B1 (en) A composition for lowering blood sugar comprising roasted licorice extract or a compound isolated therefrom
KR20230068292A (en) Composition for preventing, ameliorating or treating metabolic diseases comprising Schizonepeta tenuifolia extract as effective component
KR20240073791A (en) Composition for improving blood circulation containing herbal extracts as an active ingredient
KR102010858B1 (en) Composition for preventing or treating hangover comprising extract from germinated gemmule of bean
KR20240072591A (en) Composition for preventing, improving or treating liver disease comprising extract of Suaeda glauca as effective component
KR20240056927A (en) Composition for preventing, ameliorating or treating inflammatory bowel disease comprising Dianthus chinensis extract as effective component
KR20130072660A (en) Composition for preventing or treating cancer comprising ethyl acetate fraction from orostachys japonicus
KR20110051547A (en) Gout preventive or therapeutic composition containing blueberry leaf extract as an active ingredient
KR20190142674A (en) Pharmaceutical composition for preventing or treating liver damage comprising Curcuma longa extract
KR20190138456A (en) Pharmaceutical composition comprising Astragali radix derivatives and Lithospermi radix derivatives for anti-diabetes

Legal Events

Date Code Title Description
AS Assignment

Owner name: KOREA INSTITUTE OF ORIENTAL MEDICINE, KOREA, REPUB

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KIM, DONG SEON;REEL/FRAME:042794/0571

Effective date: 20170616

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4